Valuation : IMPACT Therapeutics, Inc

Market Cap 3.7B 4.31B 550M 472M 442M 405M 762M 52.52B 765M 5.23B 2.05B 26.47B 2.06B 2.02B 87.61B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 2.85B 3.33B 425M 364M 341M 312M 589M 40.55B 590M 4.04B 1.58B 20.44B 1.59B 1.56B 67.64B EV / Sales 2026 *
9.93x
EV / Sales 2027 * 2.56x
Free-Float
53.13%
Yield 2026 *
-
Yield 2027 * -
1 day-0.57%
1 week+15.97%
Current month+17.99%
1 month+42.56%
3 months-58.02%
1 week 12.76
Extreme 12.76
16.78
1 month 10.59
Extreme 10.59
16.78
Current year 10.31
Extreme 10.31
47.98
1 year 10.31
Extreme 10.31
47.98
3 years 10.31
Extreme 10.31
47.98
5 years 10.31
Extreme 10.31
47.98
10 years 10.31
Extreme 10.31
47.98
Manager TitleAgeSince
Chief Executive Officer 69 01/06/2014
Director of Finance/CFO 51 01/05/2024
Chief Tech/Sci/R&D Officer 44 01/01/2025
Director TitleAgeSince
Director/Board Member 69 01/06/2014
Director/Board Member 69 01/06/2014
Director/Board Member 44 01/03/2025
Change 5-day change 1-year change 3-year change Capi.($)
-0.57%+15.97% - - 553M
-0.44%-1.01%+2.91%+23.28% 51.14B
-4.41%+2.63%+460.91%+566.37% 47.4B
-0.66%+0.84%+38.82%+18.13% 43.19B
-1.33%-1.82%+23.39%+81.93% 42.35B
-2.27%-3.02%+14.22%+51.50% 33.23B
-1.45%-2.42%+28.08%+131.50% 17.07B
-0.39%-1.62% - - 16.38B
-0.03%+0.16%+12.52%+28.81% 14.76B
-2.28%-0.68%+79.63%+47.51% 14.15B
Average -1.31%+3.49%+82.56%+118.63% 28.02B
Weighted average by Cap. -1.56%+1.10%+102.27%+141.83%

Financials

2026 *2027 *
Net sales 288M 335M 42.78M 36.72M 34.38M 31.48M 59.31M 4.09B 59.47M 407M 159M 2.06B 161M 157M 6.82B 941M 1.1B 140M 120M 113M 103M 194M 13.38B 195M 1.33B 521M 6.74B 526M 514M 22.31B
Net income - -
Net Debt -842M -982M -125M -108M -101M -92.22M -174M -11.97B -174M -1.19B -466M -6.03B -471M -460M -19.96B -1.29B -1.5B -192M -164M -154M -141M -266M -18.3B -266M -1.82B -713M -9.22B -719M -704M -30.52B
Logo IMPACT Therapeutics, Inc
IMPACT Therapeutics Inc is a China-based company primarily engaged in the research, development, and commercialization of pharmaceutical products. The Company is principally engaged in the research and development of synthetic lethality-based precision anti-cancer therapies. The Company's product pipeline is primarily composed of Senaparib, as well as novel antibody-drug conjugates (ADCs) and degrader candidates. The Company distributes its products within the domestic market and to overseas markets.
Employees
-
Date Price Change Volume
28/08/26 HK$15.61 -0.57% 645,280
27/08/26 HK$15.70 +9.33% 856,600
26/08/26 HK$14.36 +1.63% 481,000
25/08/26 HK$14.13 +4.51% 377,893
24/08/26 HK$13.52 +0.45% 505,321
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
13.46CNY
Average target price
28.52CNY
Spread / Average Target
+111.84%

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 7630 Stock